Results from a multinational study have shown that Warner-Lambert's simvastatin increases HDL-cholesterol and apolipoprotein A-I levels to a significantly greater extent than Merck's atorvastatin in patients with hypercholesterolaemia. The study was one of several presented at the 48th Annual Scientific Session of the American College of Cardiology [New Orleans, US; March 1999] to investigate the efficacy of simvastatin.